Noninvasive, microbiome-based IBD diagnosis
Guselkumab for moderately to severely active UC
Mirikizumab for moderately to severely active CD
Filgotinib for moderately to severely active CD
Vedolizumab to prevent postoperative CD recurrence
Infliximab-azathioprine during steroid tapering for acute severe UC
Mucosal healing with vedolizumab in chronic pouchitis
Advanced therapies in moderately to severely active UC
Durable remission after ileocolic resection for CD
Metronidazole or vancomycin for C. difficile infection in IBD
Please login below to download this issue (PDF)